Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK139 in moderate to severe asthma
NCT07436221Phase 2Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of AK139 in asthma, sponsored by Akeso, Inc.. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
AK139
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07436221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07436221.